Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

Huntington’s disease chorea impact and prevalence

Approximately 90% of patients with Huntington’s disease (HD) experience chorea1

HD chorea starts small and progresses to larger movements_mobile HD chorea starts small and progresses to larger movements

Approximately 90% of patients with Huntington’s disease (HD) experience chorea1

Chorea typically1:

  • Initially presents as occasional small-amplitude movements of fingers, hands, and face muscles
  • Progresses to larger, more frequent movements that involve all extremities and the trunk

Chorea is cited as one of the most impactful symptoms on everyday life by both HD patients and caregivers2

Chorea may impact:

Speech/
swallowing3,4

Social/
functioning5

Daily
activities6

Walking/
gait3,7

Employment6

30%
of caregivers and
18%
of patients
rank chorea as
THE MOST IMPACTFUL
SYMPTOM OF HD2,a
a

Results of 2 separate surveys conducted by HDSA of patients with HD and caregivers of patients with HD to capture perspectives on HD symptoms and current treatments. Surveys were distributed in August and September 2014, and responses were collected through January 2015.

Patients with Huntington’s disease (HD) chorea reported requiring assistance more frequently for daily activities6

Self-care activities requiring assistance when considering chorea as an independent factor6,b,c

Emotional support

Finances

Leaving the house

Meal preparation

Daily activity
motivation

Planning daily
activities

Taking medication
when required

Using household
appliances

Patients with chorea are 2xMORE
LIKELY to require caregiver
assistance with daily
needs than those
without chorea6
b

Data were drawn from the Adelphi HD Specific Programme (DSPTM) conducted between July and October 2017. The DSPTM was a large, point-in-time survey of physicians and their patients in a real-world clinical setting and included 144 neurologists and 427 of their patients with HD in the United States. Physicians were instructed to complete a record form for their patients with HD, either retrospectively from their recent records or prospectively from their next consult.6
c

Activities that were not significantly different between patients with chorea and patients without chorea included communication with others, getting in and out of bed, going to the toilet, and gardening.6

SEE PATIENT CASES
FROM KINECT-HD

View videos of clinical trial patients with HD chorea treated with INGREZZA® (valbenazine) capsules

WATCH CASE VIDEOS

THERAPEUTIC DOSING
FROM DAY 1

The only VMAT2 inhibitor that offers an effective starting dosage you can adjust based on response and tolerability1

EXPLORE DOSING

REFERENCES:

  1. Nance MA, Paulsen JS, Rosenblatt A, Wheelock V. A Physician’s Guide to the Management of Huntington’s Disease. 3rd ed. Huntington’s Disease Society of America; 2011.
  2. Simpson JA, Lovecky D, Kogan J, Vetter LA, Yohrling GJ. Survey of the Huntington’s disease patient and caregiver community reveals most impactful symptoms and treatment needs. J Huntingtons Dis. 2016;5(4):395-403.
  3. Suchowersky O. Huntington disease: clinical features and diagnosis. Accessed March 7, 2023. https://www.uptodate.com/contents/huntington-disease-clinical-features-and-diagnosis.
  4. Roos RAC. Huntington’s disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.
  5. Sherman CW, Iyer R, Abler V, Antonelli A, Carlozzi NE. Perceptions of the impact of chorea on health-related quality of life in Huntington disease (HD): A qualitative analysis of individuals across the HD spectrum, family members, and clinicians. Neuropsychol Rehabil. 2020;30(6):1150-1168.
  6. Claassen DO, DeCourcy J, Mellor J, Johnston C, Iyer RG. Impact of chorea on self-care activity, employment, and health-care resource use in patients with Huntington’s disease. J Health Econ Outcomes Res. 2021;8(1):99-105.
  7. Grimbergen YAM, Knol MJ, Bloem BR, Kremer BPH, Roos RAC, Munneke M. Falls and gait disturbances in Huntington’s disease. Mov Disord. 2008;23(7):970-976.
  8. INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.